Get notified when AMLX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Immediate Dilution (new) — The filing states investors will experience immediate and substantial dilution because the offering price is much higher than pro forma net tangible book value per share, though exact figures are blank.
- Evergreen Provision In 2022 Plan (new) — The 2022 Plan includes automatic annual evergreen increases in share reserves without stockholder approval, creating ongoing dilution risk.
Amylyx Pharmaceuticals files $350M stock offering; terms not yet set
Filed August 18, 2026 · ~1 min read
Key Changes
-
high
Amylyx is offering common stock in a $350 million aggregate offering, but share count and price per share are not yet specified.
The Offering verify on EDGAR → -
medium
Net proceeds will fund potential US commercial launch of avexitide, manufacturing, R&D, and general corporate purposes.
Use of Proceeds verify on EDGAR → -
high
Dilution section lacks actual per-share figures; blanks for net tangible book value and dilution amounts.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade AMLX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify